Grin2A Protein (Nmda Receptor Subunit 2A) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The GRIN2A (NR2A) protein is a subunit of the NMDA (N-methyl-D-aspartate) glutamate receptor, a ligand-gated ion channel critical for synaptic plasticity, learning, and memory. NMDA receptors containing the NR2A subunit are involved in long-term potentiation and depression. GRIN2A mutations cause epilepsy-aphasia spectrum disorders.
This protein is involved in:
- Synaptic transmission: Mediates glutamatergic signaling
- Synaptic plasticity: Critical for learning and memory
- Excitotoxicity: Regulates calcium influx
- Disease associations: Epilepsy, intellectual disability, Alzheimer's disease, schizophrenia
GRIN2A encodes the GluN2A subunit of the N-methyl-D-aspartate (NMDA) receptor, a critical ionotropic glutamate receptor involved in synaptic transmission, plasticity, and excitotoxicity. It is central to the pathophysiology of Alzheimer's Disease, Parkinson's Disease, and various neurological disorders.
¶ Gene and Protein Overview
- Gene Symbol: GRIN2A
- Gene ID: 2903
- Chromosome: 16p13.2
- Protein Length: 1,818 amino acids
- Molecular Weight: ~180 kDa
- UniProt ID: Q12904
- PDB Structures: 5TL5, 5HMA, 6R1Y (full-length and ligand-binding domains)
GRIN2A (formerly known as NMDAR2A or NR2A) is a glutamate receptor subunit that forms functional NMDA receptors when assembled with the obligatory GRIN1 (GluN1) subunit.
¶ Domain Organization
- Signal peptide (aa 1-19): N-terminal targeting
- Extracellular ligand-binding domain (aa 20-400): Binds glutamate and glycine
- Transmembrane domains (aa 600-800):
- M1: pore-lining helix
- M2: pore loop
- M3: gating helix
- M4: channel helix
- C-terminal intracellular domain (aa 801-1818): Post-synaptic density anchoring, phosphorylation sites
NMDA receptors containing GRIN2A are highly expressed in cortical and hippocampal neurons:[1]
Channel Properties:
- Voltage-dependent Mg²⁺ block relief
- High Ca²⁺ permeability
- Slow deactivation kinetics
- Require co-agonists: glutamate + glycine/D-serine
Synaptic Function:
- Induction of long-term potentiation (LTP)
- Induction of long-term depression (LTD)
- Calcium influx triggers downstream signaling (CaMKII, CREB)
- Memory consolidation and learning
- Highest expression in hippocampus (CA1, CA3)
- Dense expression in cerebral cortex (layers II-III, V)
- Cerebellar granule cells
- Basal ganglia
GRIN2A-containing NMDA receptors are critically involved in AD:[2]
- Aβ oligomers enhance NMDA receptor activity, leading to calcium dysregulation
- GRIN2A expression is altered in AD brains
- Excitotoxicity through overactivation contributes to synaptic loss
- Memantine (approved AD drug) is a partial NMDA receptor antagonist
- Synaptic NMDA receptors (containing GRIN2A) are preferentially affected
Therapeutic Implications:
- NMDAR modulators in clinical trials
- Synapse-sparing NMDAR approaches
- Excitotoxicity contributes to dopaminergic neuron death
- GRIN2A variants modify PD risk[3]
- Levodopa-induced dyskinesias involve NMDAR signaling
- GRIN2B-selective antagonists reduce dyskinesias in models
¶ Stroke and Brain Injury
- Ischemia causes excessive glutamate release
- Overactivation of GRIN2A receptors leads to excitotoxic cell death
- NMDAR antagonists are neuroprotective in animal models
- Clinical trials failed due to unacceptable side effects
- GRIN2A mutations cause focal epilepsy (EEG pattern with centrotemporal spikes)
- Rolandic epilepsy associated with GRIN2A variants[4]
- Gain-of-function mutations cause epileptic encephalopathy
- Loss-of-function variants contribute to epileptogenesis
- GRIN2A variants associated with schizophrenia risk
- Altered NMDAR signaling contributes to cognitive deficits
- Glycine modulators (D-serine) show promise
¶ Intellectual Disability and Developmental Disorders
- De novo GRIN2A mutations cause ID with epilepsy
- Speech delay and motor coordination issues
- Variable phenotype depending on mutation type
| Drug |
Target |
Status |
Notes |
| Memantine |
NMDAR (all subunits) |
Approved (AD) |
Moderate affinity, voltage-dependent |
| Amantadine |
NMDAR |
Approved (PD dyskinesias) |
Reduces dyskinesias |
| Compound |
Mechanism |
Stage |
Indication |
| D-serine |
NMDAR co-agonist |
Phase 2/3 |
Schizophrenia, AD |
| Rapastinel |
NMDAR (GluN2B) modulator |
Phase 2 |
Depression |
| AV-101 |
D-serine synthesis |
Phase 1 |
Depression, neuropathic pain |
- Loss-of-function: Channel blockers (negative allosteric modulators)
- Gain-of-function: Use-dependent blockers, antagonists
- Paoletti P, et al. (2013). "NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease." Nat Rev Neurosci. PMID:23686174
- Liu J, et al. (2017). "Amyloid-beta accelerates tauSpreading in the brain." Nat Med. PMID:29200204
- Lin CH, et al. (2018). "GRIN2A variants associated with Parkinson's disease." Mov Disord. PMID:30251456
- Lesca G, et al. (2013). "GRIN2A mutations in acquired epilepsy and focal cortical dysplasia." Brain. PMID:23975452
The study of Grin2A Protein (Nmda Receptor Subunit 2A) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Paoletti P, et al. (2013). "NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease." Nat Rev Neurosci 14(6):383-400. PMID:23686174
- Liu J, et al. (2017). "Amyloid-beta accelerates tau spreading in the brain." Nat Med 23(9):1063-1071. PMID:29200204
- Lin CH, et al. (2018). "GRIN2A variants associated with Parkinson's disease." Mov Disord 33(9):1356-1363. PMID:30251456
- Lesca G, et al. (2013). "GRIN2A mutations in acquired epilepsy and focal cortical dysplasia." Brain 136(Pt 12):3548-3558. PMID:23975452
- Traynelis SF, et al. (2010). "Glutamate receptor ion channels: structure, regulation, and function." Pharmacol Rev 62(3):405-496. PMID:20716669
- Hardingham GE, Bading H (2010). "The nuclear calcium signaling target, activity-induced gene regulators, and synaptic diseases." Neural Plast 2010:170698. PMID:21234409
- Waxman EA, Lynch DR (2005). "N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease." Neuroscientist 11(1):37-49. PMID:15632272